Functionalized Nanoparticles Offer Targeted Delivery for Neurodegenerative Disorders, Overcoming BBB Challenges

Effective treatment for neurodegenerative disorders like Alzheimer's, Parkinson's, and Huntington's disease is severely hampered by the blood-brain barrier (BBB), which restricts drug access to the central nervous system. These progressive conditions involve complex pathologies including oxidative stress, mitochondrial dysfunction, protein misfolding, and neuroinflammation, leading to neuronal loss. Current therapies often fall short due to poor brain bioavailability and lack of specific targeting. Nanotechnology offers a novel approach to overcome these limitations, enabling precise delivery of therapeutic agents directly to affected brain regions.

This comprehensive review systematically analyzed recent advancements in nanoparticle-based drug delivery systems for neurodegenerative disorders. It synthesized findings from various preclinical studies and conceptual frameworks, evaluating the design principles of functionalized nanoparticles and their application in delivering diverse neuroprotective agents, antioxidants, peptides, and gene therapies. The review focused on strategies that enhance blood-brain barrier penetration, improve targeting specificity, and enable controlled drug release, integrating insights into disease pathophysiology with nanotechnology-based therapeutic approaches.

The review highlights that functionalized nanoparticles significantly enhance drug delivery to the brain, primarily by overcoming the formidable blood-brain barrier. These advanced systems achieve improved targeting specificity, ensuring therapeutic agents reach affected neuronal populations while minimizing off-target effects. Furthermore, they enable controlled and sustained drug release, which is crucial for managing chronic conditions like neurodegenerative disorders. Key mechanisms involve surface modifications that facilitate receptor-mediated transcytosis or adsorption-mediated transcytosis across the BBB. Functionalized nanoparticles have demonstrated the capacity to deliver a broad spectrum of therapeutic molecules, including small-molecule neuroprotective agents, potent antioxidants, various therapeutic peptides, and even gene therapies. This targeted delivery helps to mitigate core pathogenic processes such as oxidative stress, mitochondrial dysfunction, and neuroinflammation within the brain.

The integration of disease pathophysiology with nanotechnology-based strategies offers a promising avenue for improving therapeutic outcomes and advancing precision treatment in neurodegenerative disorders.